6-prop-2-enyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 阿朴菲
• 英文名称: 6-prop-2-enyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline
• 化学式: C₁₉H₁₉N
• 分子量: 261.4
• InChiKey: XUZBFAJJCVEMKX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• COMBINATION OF A DOPAMINE D2-RECEPTOR AGONIST AND TIOTROPIUM OR A DERIVATIVE THEROF FOR TREATING OBSTRUCTIVE AIRWAYS
  申请人：Boehringer Ingelheim Pharma GmbH & Co.KG

  公开号：EP1397134A2

  公开（公告）日：2004-03-17
• Combination of a dopamine D2-receptor agonist and tiotropium or a derivative therof for treating obstructive airways and other inflammatory diseases
  申请人：Yeadon Michael

  公开号：US20070117788A1

  公开（公告）日：2007-05-24

  The present invention relates to a combination of therapeutic agents useful in the treatment of obstructive airways and other inflammatory diseases comprising (I) a dopamine D2-receptor agonist that is therapeutically effective in the treatment of said diseases when administered by inhalation; together with (II) an anti-cholinergic agent consisting of a member selected from the group consisting of tiotropium and derivatives thereof that is therapeutically effective in the treatment of said diseases when administered by inhalation; as well as to a method of treating said obstructive airways and other inflammatory diseases comprising administering to said mammal by inhalation a therapeutically effective amount of said combination of therapeutic agents; and a pharmaceutical composition comprising a pharmaceutically acceptable carrier together with said combination of therapeutic agents; and a package containing a pharmaceutical composition for insertion into a device capable of simultaneous or sequential delivery of said pharmaceutical composition in the form of an aerosol or dry powder dispersion to said mammal, where said device is a metered dose inhaler or a dry powder inhaler. It is preferred that said dopamine D2-receptor agonist component be bromocriptine mesylate, naxagolide hydrochloride, cabergoline, pergolide mesylate, quinpirole hydrochloride, or ropinirole hydrochloride; and that said anti-cholinergic agent component be tiotropium bromide.
• [EN] TREATMENT OF OPIATE WITHDRAWAL SYNDROME<br/>[FR] TRAITEMENT DU SYNDROME DE SEVRAGE AUX OPIACES
  申请人：HAHNEMANN UNIVERSITY

  公开号：WO1996004910A1

  公开（公告）日：1996-02-22

  (EN) Opiate withdrawal syndrome is treated by administration of a D2 receptor agonist, preferably a selective D2 receptor agonist. Representative compounds include apomorphine, N-allylnoraporphine, pergolide, quinpirole, propylnorapomorphine, bromocryptine, trihydroxyaporphine, methylenedioxy-propylnoraporphine, terguride and hydroxyphenyl-N-propylpiperidine.(FR) On traite le syndrome de sevrage aux opiacés par l'administration d'un agoniste du récepteur D2, de préférence un agoniste du récepteur D2 sélectif. Les composés représentatifs comprennent: apomorphine, N-allylnoraporphine, pergolide, quinpirole, propylnorapomorphine, bromocryptine, trihydroxyaporphine, méthylènedioxy-propylnoraporphine, terguride et hydroxyphényl-N-propylpipéridine.
• [EN] COMBINATION OF A DOPAMINE D2-RECEPTOR AGONIST AND TIOTROPIUM OR A DERIVATIVE THEREOF FOR TREATING OBSTRUCTIVE AIRWAYS AND OTHER INFLAMMATORY DISEASES<br/>[FR] COMBINAISON D'UN AGONISTE DE RECEPTEUR DE DOPAMINE D2 ET DE TIOTROPIUM OU D'UN DERIVE DE CELUI-CI, DESTINEE AU TRAITEMENT DES VOIES RESPIRATOIRES OBSTRUCTIVES ET D'AUTRES MALADIES INFLAMMATOIRES
  申请人：BOEHRINGER INGELHEIM PHARMA

  公开号：WO2002096422A2

  公开（公告）日：2002-12-05

  The present invention relates to a combination of therapeutic agents useful in the treatment of obstructive airways and other inflammatory diseases comprising (I) a dopamine D2-receptor agonist that is therapeutically effective in the treatment of said diseases when administered by inhalation; together with (II) an anti-cholinergic agent consisting of a member selected from the group consisting of tiotropium and derivatives thereof that is therapeutically effective in the treatment of said diseases when administered by inhalation; as well as to a method of treating treating said obstructive airways and other inflammatory diseases comprising administering to said mammal by inhalation a therapeutically effective amount of said combination of therapeutic agents; and a pharmaceutical composition comprising a pharmaceutically acceptable carrier together with said combination of therapeutic agents; and a package containing a pharmaceutical composition for insertion into a device capable of simultaneous or sequential delivery of said pharmaceutical composition in the form of an aerosol or dry powder dispersion to said mammal, where said device is a metered dose inhaler or a dry powder inhaler. It is preferred that said dopamine D2-receptor agonist component be bromocriptine mesylate, naxagolide hydrochloride, cabergoline, pergolide mesylate, quinpirole hydrochloride, or ropinirole hydrochloride; and that said anti-cholinergic agent component be tiotropium bromide.